Lumakras Generic Name & Formulations
Tabs 120mg—240; 320mg—90
Mechanism of Action
Lumakras Dosage and Administration
Lumakras Boxed Warnings
Monitor LFTs prior to initiation, every 3 weeks during 1st 3 months of treatment, then once monthly or as clinically indicated; test more frequently if AST, ALT and/or bilirubin elevations develop. Monitor for pulmonary symptoms indicative of ILD/pneumonitis; withhold immediately if suspected and permanently discontinue if no other causes are identified. Hepatic impairment: monitor for adverse reactions more frequently. Pregnancy. Nursing mother: not recommended (during and for 1 week after the last dose).
Median time to peak plasma concentration: 1 hour.
Effect of Food:
Sotorasib AUC0-24h increased by 25% when administered with a high-fat, high-calorie meal compared to administration under fasted conditions.
Mean volume of distribution at steady state: 211 L.
89% plasma protein bound.
Fecal (74%), renal (6%).
Half-life: 5 hours. Apparent clearance at steady state: 26.2 L/hr.
Avoid concomitant PPIs, H2-receptor antagonists, and locally acting antacids; if unavoidable, give Lumakras 4hrs before or 10hrs after antacid. Antagonized by strong CYP3A4 inducers (eg, rifampin); avoid. Avoid concomitant sensitive CYP3A4 substrates (eg, midazolam); if unavoidable, increase the CYP3A4 substrate dosage. Avoid concomitant P-gp substrates (eg, digoxin); if unavoidable, decrease the P-gp substrate dosage. Potentiates BCRP substrates; monitor for adverse reactions and decrease the BCRP substrate dose.
Lumakras Adverse Reactions
Lumakras Clinical Trials
Lumakras Patient Counseling